Athera Elects New Chairman of the Board
News Sep 23, 2013
Athera Biotechnologies AB has announced that Gunnar Olsson, former head of the global CV/GI team in AstraZeneca, has been elected new Chairman of the Board.
Earlier this year, Tomas Odergren, VP Clinical Development at Karolinska Development AB, joined the Board of Directors.
The extraordinary shareholders meeting in Athera has elected Gunnar Olsson new Chairman of the Board after Per Sjöberg, who has been leading the company for eight years.
Dr Olsson joins Athera after 24 years in AstraZeneca, where he has held several senior management positions, mainly within therapy area leadership for cardiovascular and gastrointestinal disease.
He holds an MD and PhD from Karolinska Institutet and is specialist in Cardiology and Internal Medicine. Dr Olsson is Honorary Doctor of Medicine at Gothenburg University.
Tomas Odergren, MD, PhD and specialist in Neurology, joined the Board of Directors at the Annual General Meeting in June, and he brings an excellent and well-timed expertise in clinical development. Otto Skolling remains on the Board, while Paul de Potocki and Per Sjöberg resign.
“I am very pleased to hand over to a Chairman with such strong experience from industrial drug development and business” says Per Sjöberg. “Gunnar has an extensive international network and expertise in cardiovascular drug development, and both he and Tomas will be able to make great contributions to the next development phases in Athera.”
The company has recently moved their office to new premises at Business Center on Sankt Eriksgatan 117 in Stockholm, next to Hagastaden and the new Karolinska Hospital.
The Role of Secretory Autophagy in Intestinal DefenseNews
Researchers from UT Southwestern have determined that secretory autophagy plays a role in intestinal defense, and suggest why mutations in this system are associated with Crohn's disease.
Could This Be a "Silver Bullet" for Preventing and Treating Colon Cancer?News
A team of scientists targeted the gene CtBP with a drug known as HIPP (2-hydroxy-imino phenylpyruvic acid) and were able to reduce the development of pre-cancerous polyps by half.READ MORE
Comments | 0 ADD COMMENT
8th International Symposium on Recent Advances in Food Analysis (RAFA 2017)
Nov 07 - Nov 10, 2017
6th Edition of International Conference on Pharmacognosy and Medicinal Plants
Apr 16 - Apr 17, 2018